![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Liste des catégories
AlcoolismeAlzheimer Et ParkinsonAnalgésiquesAnti-inflammatoiresAntiallergiquesAntibiotiquesAnticonvulsivantsAntidépresseursAntifongiquesAntiparasitairesAntivirauxArthriteAsthmeCancerChirurgieCholestérolContraceptifsDiabèteDiurétiquesDysfonction érectileHypertension ArtérielleMaladies CardiovasculairesMigrainesObésitéOstéoporoseRelaxants MusculairesSanté FéminineSanté MasculineSoins De La PeauSoins Des YeuxTractus Gastro-intestinalTroubles MentauxTroubles NeurologiquesV I HVoies RespiratoiresVoies Urinaires 09 May 2012 16:42:40
4 Reasons Merck Will Break $40 By 20134 Reasons Merck Will Break $40 By 2013 Seeking Alpha Much of this is thanks to the fact that Merck has been more fiscally responsible, by working with lower marketing and production costs, while at the same time, cutting the prices on Hyzaar and Cozaar, two blood pressure medications that have not been ...
07 May 2012 04:33:53
Top global pharma cos post sales growth of just 3.4%, but net profit up by ...Top global pharma cos post sales growth of just 3.4%, but net profit up by ... pharmabiz.com ... Lovenox (Sanofi-aventis), Remicade (Merck), Plavix (Sanofi-aventis), Aranesp and Epogen (Amgen), Vytorin (Merck), Aprovel CoAprovel (sanofi-aventis), Cozaar Hyzaar (Merck) Procrit Eprex (J&J), Pegasys (Roche) and Zometa (Novartis) received setback ...
30 Apr 2012 20:50:18
1 Unexcitingly Good Dividend Play1 Unexcitingly Good Dividend Play DailyFinance Right now it's Merck's heart drugs Cozaar and Hyzaar , which plummeted 21% in the first quarter. Upcoming is top-selling Singulair, which will begin seeing generic competition in the US in August. The company hopes to keep 2012 sales constant compared ...
30 Apr 2012 09:54:30
Strong profit growth and Zetia patent win for Merck & CoStrong profit growth and Zetia patent win for Merck & Co Pharma Times Revenues from the antihypertensives Cozaar (losartan) and Hyzaar (losartan plus hydrochlorothiazide) fell 21% to $336 million, due to generic competition. The anti-inflammatory Remicade (infliximab), the Johnson & Johnson drug which Merck sells outside ...
27 Apr 2012 13:20:21
Merck Posts Big Q1 Profit Jump on Lower Charges ABC News Merck Posts Big Q1 Profit Jump on Lower Charges ABC News Together, they brought in $1.31 billion, helping make up for generic competition continuing to slash sales of former blockbusters Cozaar and Hyzaar , for high blood presure. Gardasil and HIV drug Isentress both had double-digit sales growth. Merck Beats by a Penny; Affirms View - Analyst Blog Merck Announces First-Quarter 2012 Financial Results27 Apr 2012 13:19:55
Drugmaker Merck's Q1 profit jumps 67 pct. on lower spending, despite lower ... Bloomberg Drugmaker Merck's Q1 profit jumps 67 pct. on lower spending, despite lower ... Washington Post They brought in a total of $1.31 billion, helping make up for generic competition continuing to slash sales of former blockbusters Cozaar and Hyzaar , for high blood presure. Merck recently got US approval to sell an extended-release version of Janumet, ... Merck Stirs Up 67% Jump in 1Q Profit Merck Announces First-Quarter 2012 Financial Results |
|
Choose Your language:
Recherche sur le site
Testimonials
Salut, merci
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Bestsellers|Politique|Questions fréquentes|Testimonials|Contactez-nous|Sitemap |
|
|
|
|
| |